

Market insights summary

Asia Pacific structural heart closure device market

What's trending?

Demographic shifts and stronger clinical evidence are redirecting closure growth away from pediatric cases and toward adult-centric therapies.

- Left atrial appendage (LAA) closure is the primary procedural growth engine in structural heart closure device procedures, supported by rising atrial fibrillation (AF) prevalence, maturing long-term evidence, and increasing use of concomitant AF ablation and LAA closure in high-volume centers.
- Declining birth rates are structurally constraining congenital heart defect closure volumes, steadily shifting market growth reliance towards adult-centric therapies like LAA and patent foramen ovale (PFO) closure.

Volume-based procurement (VBP)-related pricing pressures in Mainland China are reshaping competitor portfolio strategy

- In Mainland China, domestic manufacturers are gaining share by optimizing bid competitiveness, local manufacturing scale, and tender execution.
- With affordability and access considerations playing a larger role in market dynamics in Mainland China, procedural expansion is outpacing revenue growth.

Access more insights and data in the [report](#). [Speak to our team](#) to see how we can power your innovation.

2024 Asia Pacific structural heart closure device market snapshot


\$624.2M

Market value


9.3%

CAGR ('19-'34)


2024 Asia Pacific structural heart closure device by product type



2024 Asia Pacific structural heart closure device procedure volume growth by indication



Asia Pacific structural heart closure device market, 2024 and 2034



2024 Asia Pacific structural heart closure device competitive landscape

